CN101596252A - 一种治疗带状疱疹的组合物及其制备方法 - Google Patents
一种治疗带状疱疹的组合物及其制备方法 Download PDFInfo
- Publication number
- CN101596252A CN101596252A CNA2009101581504A CN200910158150A CN101596252A CN 101596252 A CN101596252 A CN 101596252A CN A2009101581504 A CNA2009101581504 A CN A2009101581504A CN 200910158150 A CN200910158150 A CN 200910158150A CN 101596252 A CN101596252 A CN 101596252A
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- herpes zoster
- treatment
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 88
- 208000007514 Herpes zoster Diseases 0.000 title claims abstract description 47
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 24
- 239000000843 powder Substances 0.000 claims description 42
- 238000000605 extraction Methods 0.000 claims description 33
- 238000010438 heat treatment Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 31
- 210000004369 blood Anatomy 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 30
- 208000002193 Pain Diseases 0.000 abstract description 27
- 230000036407 pain Effects 0.000 abstract description 27
- 201000010099 disease Diseases 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 231100000614 poison Toxicity 0.000 abstract description 12
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 239000003440 toxic substance Substances 0.000 abstract description 9
- 231100000241 scar Toxicity 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 6
- 208000004296 neuralgia Diseases 0.000 abstract description 5
- 238000005469 granulation Methods 0.000 abstract description 4
- 230000003179 granulation Effects 0.000 abstract description 4
- 230000001338 necrotic effect Effects 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 4
- 239000002552 dosage form Substances 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 43
- -1 iodouracil desoxyriboside Chemical class 0.000 description 26
- 239000000243 solution Substances 0.000 description 23
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 20
- 239000008399 tap water Substances 0.000 description 20
- 235000020679 tap water Nutrition 0.000 description 20
- 229930182470 glycoside Natural products 0.000 description 19
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 14
- 239000000284 extract Substances 0.000 description 12
- 230000001717 pathogenic effect Effects 0.000 description 12
- 150000002338 glycosides Chemical class 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 206010037844 rash Diseases 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 238000001035 drying Methods 0.000 description 9
- 201000005884 exanthem Diseases 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 230000000144 pharmacologic effect Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 208000010201 Exanthema Diseases 0.000 description 8
- 208000001848 dysentery Diseases 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 7
- 206010023126 Jaundice Diseases 0.000 description 7
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 239000000341 volatile oil Substances 0.000 description 7
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000036461 convulsion Effects 0.000 description 6
- 208000001780 epistaxis Diseases 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 210000000232 gallbladder Anatomy 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 239000010282 Emodin Substances 0.000 description 4
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 4
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 4
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 4
- 241001071917 Lithospermum Species 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 4
- WNFXUXZJJKTDOZ-HNNXBMFYSA-N [(1s)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] acetate Chemical compound C1=CC(O)=C2C(=O)C([C@@H](OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-HNNXBMFYSA-N 0.000 description 4
- 229960004150 aciclovir Drugs 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
- PTOJXIKSKSASRB-UHFFFAOYSA-O candicine Chemical compound C[N+](C)(C)CCC1=CC=C(O)C=C1 PTOJXIKSKSASRB-UHFFFAOYSA-O 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 4
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 4
- 229940097275 indigo Drugs 0.000 description 4
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 4
- IGGUPRCHHJZPBS-UHFFFAOYSA-N nonacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCC IGGUPRCHHJZPBS-UHFFFAOYSA-N 0.000 description 4
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 4
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- WNFXUXZJJKTDOZ-UHFFFAOYSA-N shikonin acetate Natural products C1=CC(O)=C2C(=O)C(C(OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-UHFFFAOYSA-N 0.000 description 4
- 206010040882 skin lesion Diseases 0.000 description 4
- 231100000444 skin lesion Toxicity 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 3
- 201000000297 Erysipelas Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 description 3
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 3
- 229930003779 Vitamin B12 Natural products 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000010231 banlangen Substances 0.000 description 3
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 3
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 3
- 229940093265 berberine Drugs 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 3
- 235000001785 ferulic acid Nutrition 0.000 description 3
- 229940114124 ferulic acid Drugs 0.000 description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 3
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 3
- 229940032091 stigmasterol Drugs 0.000 description 3
- 235000016831 stigmasterol Nutrition 0.000 description 3
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 235000019163 vitamin B12 Nutrition 0.000 description 3
- 239000011715 vitamin B12 Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 2
- YSCJAYPKBYRXEZ-HZPINHDXSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YSCJAYPKBYRXEZ-HZPINHDXSA-N 0.000 description 2
- YDZWHGJRWMQCDP-NKILCQAGSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-[(2s,3r,4 Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YDZWHGJRWMQCDP-NKILCQAGSA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 description 2
- YLRXAIKMLINXQY-ZDUSSCGKSA-O (S)-magnoflorine Chemical compound C1=C(OC)C(O)=C2C3=C(O)C(OC)=CC=C3C[C@@H]3[N+](C)(C)CCC1=C23 YLRXAIKMLINXQY-ZDUSSCGKSA-O 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- XXLFLUJXWKXUGS-UHFFFAOYSA-N 6-methoxyquinoline-4-carboxylic acid Chemical compound N1=CC=C(C(O)=O)C2=CC(OC)=CC=C21 XXLFLUJXWKXUGS-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 2
- UNHHWEHQUUGKEE-MLLLWRCASA-N Amurensin Chemical compound C1=C(O)C(C(C(O)=C(O2)C=3C=CC(O)=CC=3)=O)=C2C(CCC(C)(O)C)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UNHHWEHQUUGKEE-MLLLWRCASA-N 0.000 description 2
- HDQHRTXBXYQUNW-CABCVRRESA-N Amurensine Natural products O(C)c1c(O)cc2[C@H]3c4c(cc5OCOc5c4)C[C@H](N(C)C3)c2c1 HDQHRTXBXYQUNW-CABCVRRESA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- GYFSYEVKFOOLFZ-UHFFFAOYSA-N Berberrubine Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(O)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 GYFSYEVKFOOLFZ-UHFFFAOYSA-N 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- DXENDDMPDZMHSQ-UHFFFAOYSA-N Candinine Chemical compound C12=NC3=CC=CC=C3C(=O)N1C1=CC=CC=C1C2=C1C(=O)C2=CC=CC=C2N1 DXENDDMPDZMHSQ-UHFFFAOYSA-N 0.000 description 2
- 244000247747 Coptis groenlandica Species 0.000 description 2
- 235000002991 Coptis groenlandica Nutrition 0.000 description 2
- 241000218176 Corydalis Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- GLNRAZLQBMAROT-UHFFFAOYSA-N Gentioflavine Chemical compound O=C1OCCC2=C(C=O)C(C)NC=C21 GLNRAZLQBMAROT-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 2
- 241000589902 Leptospira Species 0.000 description 2
- KYEAXNAYHSCLMT-CVVGWEDFSA-N Magnoflorine Natural products C[C@H]1OC=C2[C@@H]3[C@@H]1CN4CCc5c([nH]c6ccccc56)[C@@H]4[C@@H]3OC2=O KYEAXNAYHSCLMT-CVVGWEDFSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- KEQFTVQCIQJIQW-UHFFFAOYSA-N N-Phenyl-2-naphthylamine Chemical compound C=1C=C2C=CC=CC2=CC=1NC1=CC=CC=C1 KEQFTVQCIQJIQW-UHFFFAOYSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- MAYJEFRPIKEYBL-OASIGRBWSA-N Obacunone Chemical compound C=1([C@@H]2OC(=O)[C@H]3O[C@@]43[C@]3(C)C(=O)C[C@H]5C(C)(C)OC(=O)C=C[C@]5(C)[C@H]3CC[C@]42C)C=COC=1 MAYJEFRPIKEYBL-OASIGRBWSA-N 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 239000008896 Opium Substances 0.000 description 2
- 208000004224 Opium Dependence Diseases 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 2
- BQLZQPGWNVTIHR-UHFFFAOYSA-N Phellavin Natural products C1=C2OC(C=3C=CC(O)=CC=3)=C(O)C(=O)C2=C(O)C(CCC(C)(O)C)=C1OC1OC(CO)C(O)C(O)C1O BQLZQPGWNVTIHR-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000219050 Polygonaceae Species 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 240000004980 Rheum officinale Species 0.000 description 2
- 235000008081 Rheum officinale Nutrition 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 241001593750 Turcica Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 2
- 241001251949 Xanthium sibiricum Species 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- UNHHWEHQUUGKEE-UHFFFAOYSA-N amurensin Natural products C1=C(O)C(C(C(O)=C(O2)C=3C=CC(O)=CC=3)=O)=C2C(CCC(C)(O)C)=C1OC1OC(CO)C(O)C(O)C1O UNHHWEHQUUGKEE-UHFFFAOYSA-N 0.000 description 2
- 150000001454 anthracenes Chemical class 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- GLYPKDKODVRYGP-UHFFFAOYSA-O berberrubine Natural products C1=C2CC[N+]3=CC4=C(O)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 GLYPKDKODVRYGP-UHFFFAOYSA-O 0.000 description 2
- GLYPKDKODVRYGP-UHFFFAOYSA-N burberrubine Natural products C12=CC=3OCOC=3C=C2CCN2C1=CC1=CC=C(OC)C(=O)C1=C2 GLYPKDKODVRYGP-UHFFFAOYSA-N 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- FJSOHLNMRNSYFR-OPDZODGYSA-N epimedoside C Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(C/C=C(\C)/C)c2OC(c3ccc(O)cc3)=C(O)C(=O)c2c(O)c1 FJSOHLNMRNSYFR-OPDZODGYSA-N 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- DFNZYFAJQPLJFI-UHFFFAOYSA-N gentianine Chemical compound O=C1OCCC2=C1C=NC=C2C=C DFNZYFAJQPLJFI-UHFFFAOYSA-N 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- VSLDMVSILHVDSR-UHFFFAOYSA-N obacunone Natural products CC1(C)OC(=O)C=CC2(C)C1CC(=O)C3(C)C2CCC4(C)C(OC(=O)C5OC345)c6occc6 VSLDMVSILHVDSR-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 229960001027 opium Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- LKOJGSWUMISDOF-UHFFFAOYSA-N oroxylin A Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=CC=C1 LKOJGSWUMISDOF-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 2
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 235000014102 seafood Nutrition 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 210000001032 spinal nerve Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229920001864 tannin Chemical class 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Chemical class 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 229940093257 valacyclovir Drugs 0.000 description 2
- 229960003636 vidarabine Drugs 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- ZJSJQWDXAYNLNS-UHFFFAOYSA-N (+) pinoresinol-4,4'-di-O-beta-D-glucopyranoside Natural products COC1=CC(C2C3C(C(OC3)C=3C=C(OC)C(OC4C(C(O)C(O)C(CO)O4)O)=CC=3)CO2)=CC=C1OC1OC(CO)C(O)C(O)C1O ZJSJQWDXAYNLNS-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WMBOCUXXNSOQHM-FLIBITNWSA-N (Z)-3-butylidenephthalide Chemical compound C1=CC=C2C(=C/CCC)/OC(=O)C2=C1 WMBOCUXXNSOQHM-FLIBITNWSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RNKMOGIPOMVCHO-SJMVAQJGSA-N 1,3,6-trigalloyl glucose Chemical class C([C@@H]1[C@H]([C@@H]([C@@H](O)[C@H](OC(=O)C=2C=C(O)C(O)=C(O)C=2)O1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 RNKMOGIPOMVCHO-SJMVAQJGSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- GDVRUDXLQBVIKP-HQHREHCSSA-N 1-O-galloyl-beta-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(=O)C1=CC(O)=C(O)C(O)=C1 GDVRUDXLQBVIKP-HQHREHCSSA-N 0.000 description 1
- LAOOXBLMIJHMFO-UHFFFAOYSA-N 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one;hydron;chloride Chemical compound Cl.S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC LAOOXBLMIJHMFO-UHFFFAOYSA-N 0.000 description 1
- MUVQKFGNPGZBII-UHFFFAOYSA-N 1-anthrol Chemical compound C1=CC=C2C=C3C(O)=CC=CC3=CC2=C1 MUVQKFGNPGZBII-UHFFFAOYSA-N 0.000 description 1
- BUCJHJXFXUZJHL-UHFFFAOYSA-N 1-ethylcyclohexan-1-ol Chemical class CCC1(O)CCCCC1 BUCJHJXFXUZJHL-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- YXACCHLOUSCDDR-UHFFFAOYSA-N 3,5-dihydroxy-6-(3-hydroxy-3-methylbutyl)-2-(4-hydroxyphenyl)-7-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3-dihydrochromen-4-one Chemical compound CC(C)(O)CCC1=C(O)C=2C(=O)C(O)C(C=3C=CC(O)=CC=3)OC=2C=C1OC1OC(CO)C(O)C(O)C1O YXACCHLOUSCDDR-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- URQMEZRQHLCJKR-UHFFFAOYSA-N 3-Methyl-5-propyl-2-cyclohexen-1-one Chemical compound CCCC1CC(C)=CC(=O)C1 URQMEZRQHLCJKR-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- GKAJCVFOJGXVIA-UHFFFAOYSA-N 4'-methoxy-3,3',5-stilbenetriol 3-glucoside Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(O)=CC(OC2C(C(O)C(O)C(CO)O2)O)=C1 GKAJCVFOJGXVIA-UHFFFAOYSA-N 0.000 description 1
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- IPQVTOJGNYVQEO-LALZNDFESA-N 9-[(9r)-2-carboxy-4-hydroxy-10-oxo-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracene-2-carboxylic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1C2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-LALZNDFESA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- QQUHMASGPODSIW-UHFFFAOYSA-N Albiflorin Natural products C=1C=CC=CC=1C(=O)OCC12C(=O)OC3(C)CC(O)C1CC32OC1OC(CO)C(O)C(O)C1O QQUHMASGPODSIW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241001050829 Arnebia guttata Species 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 244000025352 Artocarpus heterophyllus Species 0.000 description 1
- 235000008725 Artocarpus heterophyllus Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- NEZONWMXZKDMKF-UHFFFAOYSA-N C.I. Natural Red 20 Chemical compound C1=CC(O)=C2C(=O)C(C(O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 244000025596 Cassia laevigata Species 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 244000089795 Clausena lansium Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000037803 Coptis deltoidea Species 0.000 description 1
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 1
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 1
- AQASRZOCERRGBL-UHFFFAOYSA-N Dauricine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C1CC1=CC=C(O)C(OC2=CC=C(C=C2)CC2N(C)CCC=3C=C(C(=CC=32)OC)OC)=C1 AQASRZOCERRGBL-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- QWCNQXNAFCBLLV-IAGOWNOFSA-N Falcarindiol Natural products CCCCCCCC=C/[C@@H](O)C#CC#C[C@H](O)C=C QWCNQXNAFCBLLV-IAGOWNOFSA-N 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 241000486199 Gentiana rigescens Species 0.000 description 1
- 241001071804 Gentianaceae Species 0.000 description 1
- YXEZXGJYPKMKEJ-UHFFFAOYSA-N Gentianin Natural products C=Cc1cc2CCOC(=O)c2cn1 YXEZXGJYPKMKEJ-UHFFFAOYSA-N 0.000 description 1
- 229920000296 Glucogallin Polymers 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000003809 Herpes Zoster Ophthalmicus Diseases 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 241000334160 Isatis Species 0.000 description 1
- BVRYLTBIGIAADD-MRXNPFEDSA-N Isobutylshikonin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](CC=C(C)C)OC(=O)C(C)C)=CC(=O)C2=C1O BVRYLTBIGIAADD-MRXNPFEDSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- JGWYMAUEOSXSLU-UHFFFAOYSA-N Lactiflorin Natural products CC12CC(=O)C3CC(COC(=O)c4ccccc4)(C3O1)C25OC6OC(CO)C(O)C(O)C6O5 JGWYMAUEOSXSLU-UHFFFAOYSA-N 0.000 description 1
- 240000004035 Lithospermum officinale Species 0.000 description 1
- 235000011030 Lithospermum officinale Nutrition 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241000607292 Maguireothamnus speciosus Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- VLCHQFXSBHIBRV-KNNWKXJLSA-N Mussaenosidic acid Natural products O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@@H]3[C@@H](O)[C@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@](O)(C)CC2 VLCHQFXSBHIBRV-KNNWKXJLSA-N 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010030865 Ophthalmic herpes zoster Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 206010033081 Otitis media chronic Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 241000124449 Paeonia obovata Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000382362 Persicaria tinctoria Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- BQLZQPGWNVTIHR-AWGWVDLJSA-N Phellatin Chemical compound C1=C2OC(C=3C=CC(O)=CC=3)=C(O)C(=O)C2=C(O)C(CCC(C)(O)C)=C1O[C@@H]1OC(CO)[C@@H](O)[C@H](O)C1O BQLZQPGWNVTIHR-AWGWVDLJSA-N 0.000 description 1
- RBBVPNQTBKHOEQ-KKSFZXQISA-O Phellodendrine Chemical compound C1CC2=CC(OC)=C(O)C=C2[C@H]2[N@+]1(C)CC(C=C(C(=C1)O)OC)=C1C2 RBBVPNQTBKHOEQ-KKSFZXQISA-O 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000205407 Polygonum Species 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000545442 Radix Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- RLTYFLICIIZAKQ-UHFFFAOYSA-N Rhababerone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C=C(C)C(O)=C2 RLTYFLICIIZAKQ-UHFFFAOYSA-N 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 235000008090 Rheum palmatum Nutrition 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Chemical class OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 101000874322 Scutellaria baicalensis Baicalin-beta-D-glucuronidase Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 240000005498 Setaria italica Species 0.000 description 1
- YSIFYNVXJOGADM-KDYWOABDSA-N Shanzhiside Chemical compound O([C@H]1[C@H]2[C@@H](C(=CO1)C(O)=O)[C@H](O)C[C@@]2(O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YSIFYNVXJOGADM-KDYWOABDSA-N 0.000 description 1
- PVPIPGMAEAJMTH-UHFFFAOYSA-N Shanzhiside Natural products OCC1OC(OC2OC=C(C3C(O)CC(O)C23)C(=O)O)C(O)C(O)C1O PVPIPGMAEAJMTH-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229930192484 Skullcapflavone Natural products 0.000 description 1
- CZRGNFVQUYWGKP-UHFFFAOYSA-N Skullcapflavone I Natural products COC=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1O CZRGNFVQUYWGKP-UHFFFAOYSA-N 0.000 description 1
- HKOIDIVCPUDLBS-UHFFFAOYSA-N Skullcapflavone II Natural products Oc1cccc(O)c1C2=CC(=O)c3c(O)c(O)c(O)c(O)c3O2 HKOIDIVCPUDLBS-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 206010042170 Strangury Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical class C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Chemical group 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- VSJGJMKGNMDJCI-ZASXJUAOSA-N Sweroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@H](CCOC2=O)C2=CO1 VSJGJMKGNMDJCI-ZASXJUAOSA-N 0.000 description 1
- HEYZWPRKKUGDCR-QBXMEVCASA-N Swertiamarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@]2(O)CCOC(=O)C2=CO1 HEYZWPRKKUGDCR-QBXMEVCASA-N 0.000 description 1
- HEYZWPRKKUGDCR-WRMJXEAJSA-N Swertiamarin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)[C@@]2(O)C(C(=O)OCC2)=CO1 HEYZWPRKKUGDCR-WRMJXEAJSA-N 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 244000299492 Thespesia populnea Species 0.000 description 1
- 235000009430 Thespesia populnea Nutrition 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- BJBKXYIIWYIZCX-UHFFFAOYSA-N Trigraecum Natural products C1=C(O)C(OC)=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 BJBKXYIIWYIZCX-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-UHFFFAOYSA-N Wogonoside Natural products C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1OC1OC(C(O)=O)C(O)C(O)C1O LNOHXHDWGCMVCO-UHFFFAOYSA-N 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OPXFZJLGAZHBMA-BUOGMGTNSA-N [(z)-[(1e)-1-(carbamothioylhydrazinylidene)-3-(1,3-dioxoisoindol-2-yl)butan-2-ylidene]amino]thiourea Chemical compound C1=CC=C2C(=O)N(C(C)\C(\C=N\NC(N)=S)=N\NC(N)=S)C(=O)C2=C1 OPXFZJLGAZHBMA-BUOGMGTNSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000001272 acylglucoses Chemical class 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- QQUHMASGPODSIW-ICECTASOSA-N albiflorin Chemical compound O([C@@]12C[C@H]3[C@H](O)C[C@@]1(OC(=O)[C@]32COC(=O)C=1C=CC=CC=1)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QQUHMASGPODSIW-ICECTASOSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229930182482 anthraquinone glycoside Natural products 0.000 description 1
- 229940098421 anthraquinone glycoside Drugs 0.000 description 1
- 150000008139 anthraquinone glycosides Chemical class 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 239000008338 calamine lotion Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 108091008690 chemoreceptors Proteins 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 230000035603 choleresis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000010354 chronic purulent otitis media Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- YYFOFDHQVIODOQ-UHFFFAOYSA-O columbamine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)O)OC)CC3)[N+]3=CC2=C1OC YYFOFDHQVIODOQ-UHFFFAOYSA-O 0.000 description 1
- CYOURJWVXZHEPP-UHFFFAOYSA-N columbamine Natural products COc1cc2CCN3Cc4c(OC)c(OC)ccc4C=C3c2cc1O CYOURJWVXZHEPP-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- LUXPUVKJHVUJAV-UHFFFAOYSA-M coptisine, chloride Chemical compound [Cl-].C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 LUXPUVKJHVUJAV-UHFFFAOYSA-M 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- AQASRZOCERRGBL-ROJLCIKYSA-N dauricine Chemical compound CN1CCC2=CC(OC)=C(OC)C=C2[C@H]1CC1=CC=C(O)C(OC2=CC=C(C=C2)C[C@H]2N(C)CCC=3C=C(C(=CC=32)OC)OC)=C1 AQASRZOCERRGBL-ROJLCIKYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- MGRRGKWPEVFJSH-UHFFFAOYSA-N dianthrone Natural products C12=CC=CC=C2C(=O)C2=CC=CC=C2C1=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MGRRGKWPEVFJSH-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- RMDMBHQVNHQDDD-VFWKRBOSSA-L disodium;(2e,4e,6e,8e,10e,12e,14e)-2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioate Chemical compound [Na+].[Na+].[O-]C(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C([O-])=O RMDMBHQVNHQDDD-VFWKRBOSSA-L 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000000095 emetic effect Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- FPJQGFLUORYYPE-UHFFFAOYSA-N epiberberine Chemical compound C1=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C2OCOC2=C1 FPJQGFLUORYYPE-UHFFFAOYSA-N 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- QWCNQXNAFCBLLV-YWALDVPYSA-N falcarindiol Chemical compound CCCCCCC\C=C/[C@H](O)C#CC#C[C@H](O)C=C QWCNQXNAFCBLLV-YWALDVPYSA-N 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- XOXYHGOIRWABTC-UHFFFAOYSA-N gentisin Chemical compound C1=C(O)C=C2C(=O)C3=C(O)C=C(OC)C=C3OC2=C1 XOXYHGOIRWABTC-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- BVRYLTBIGIAADD-UHFFFAOYSA-N isobutyryl shikonin Natural products C1=CC(O)=C2C(=O)C(C(CC=C(C)C)OC(=O)C(C)C)=CC(=O)C2=C1O BVRYLTBIGIAADD-UHFFFAOYSA-N 0.000 description 1
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- AGRYIZUKIKYUFX-DNITZUGTSA-N lactiflorin Chemical compound C([C@@]12[C@]34C[C@H]2C(=O)C[C@H]1O[C@@]3(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O4)C)OC(=O)C1=CC=CC=C1 AGRYIZUKIKYUFX-DNITZUGTSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000008629 longdanxiegan Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 201000008836 maxillary sinusitis Diseases 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- WMBOCUXXNSOQHM-UHFFFAOYSA-N n-butylidenephthalide Natural products C1=CC=C2C(=CCCC)OC(=O)C2=C1 WMBOCUXXNSOQHM-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000009835 oxypaeoniflora Substances 0.000 description 1
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 description 1
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Natural products OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 235000002252 panizo Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- NJGBTKGETPDVIK-UHFFFAOYSA-N raspberry ketone Chemical compound CC(=O)CCC1=CC=C(O)C=C1 NJGBTKGETPDVIK-UHFFFAOYSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 150000004492 retinoid derivatives Chemical group 0.000 description 1
- GKAJCVFOJGXVIA-QGLKVJOYSA-N rhaponticin Natural products COc1ccc(C=Cc2cc(O)cc(O[C@@H]3O[C@@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1O GKAJCVFOJGXVIA-QGLKVJOYSA-N 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000001843 schistosomicidal effect Effects 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- GMQFOKBGMKVUQZ-UHFFFAOYSA-N scullcapflavone II Chemical compound COC1=CC=CC(O)=C1C1=CC(=O)C2=C(O)C(OC)=C(OC)C(OC)=C2O1 GMQFOKBGMKVUQZ-UHFFFAOYSA-N 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000005720 sucrose Chemical group 0.000 description 1
- VSJGJMKGNMDJCI-QXSNVGMTSA-N sweroside Natural products OC[C@H]1O[C@H](O[C@@H]2OC=C3[C@@H](CCOC3=O)[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O VSJGJMKGNMDJCI-QXSNVGMTSA-N 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- GKAJCVFOJGXVIA-DXKBKAGUSA-N trans-rhaponticin Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C1=CC(O)=CC(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 GKAJCVFOJGXVIA-DXKBKAGUSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-NTKSAMNMSA-N wogonin 7-O-beta-D-glucuronide Chemical compound C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LNOHXHDWGCMVCO-NTKSAMNMSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
- 239000010056 xuefu Substances 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
- RNWHGQJWIACOKP-UHFFFAOYSA-N zinc;oxygen(2-) Chemical compound [O-2].[Zn+2] RNWHGQJWIACOKP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开一种用于治疗带状疱疹的组合物及其制备方法,该带状疱疹组合物由如下原料制成:黄连、黄芩、黄柏、大黄、龙胆草、紫草、赤芍、当归、青黛、虎杖、连翘、栀子,针对带状疱疹形成的病因和病机,利用多种中药的活性成分的相互协同作用,通过清热解毒,燥湿止痛、化瘀败毒、去腐生肌,治疗带状疱疹,而且不留疤痕和神经痛等后遗症。本发明制备的带状疱疹组合物,可以被制备成任何一种常用的内服剂型或外用制剂,对带状疱疹的疗效显著,总有效率达到100%,本发明组合物针对带状疱疹的发病机理和提高机体免疫力,标本兼治、疗程短、费用低、疗效高对人体无副作用。
Description
技术领域
本发明涉及一种中成药及其制备方法,特别涉及一种治疗带状疱疹药物组合物及其制备方法。
背景技术
带状疱疹(herpes zoster)是由水痘-带状疱疹病毒感染引起的一种以沿周围神经分布的群集疱疹和神经痛为特征的病毒性皮肤病,在春季最易流行。带状疱疹的发病部位60%以上是在胸腰部位,因此民间又有“串腰龙”、“缠腰火丹”的俗称。由于带状疱疹病毒有亲神经的特点,发病时总是沿着神经的走向,沿周神经围分布,排列成带状呈条带状。
现代医学认为该病是带状疱疹病毒由呼吸道感染侵入体内,潜伏到脊神经或其他神经的神经细胞中。这种病毒平时可以不发病,但是由于老年人以及身体虚弱的人免疫力降低,在遇到身体劳累、感冒等情况下,容易诱发带状疱疹。
中医学认为带状疱疹是感受毒邪,湿,热,风,火郁于心、肝、肺、脾,经络阻隔,气血凝滞而成。因情志内伤,心肝气郁化热,热郁久而化火,火热溢于肌表,流窜经络,再感风、火邪毒,使气血郁闭,出现红斑、丘疤疹、痒痛等症;脾失健运而生湿,脾湿蕴结而化热,湿热外发肌肤,再感湿热邪毒,使肺的宣发、肃降、治节功能紊乱,致水液循经络闭聚于肌表,则见水疙累累如珠:湿热风火邪毒,损伤经络,经气不宣,气滞血癖,不通则痛,常致疼痛不休或刺痛不断。因此,中医治疗带状疤疹分为:肝经湿热型;脾胃湿热型;气滞血癖型等,辩证治疗取得很好的疗效,而且不复发。
带状病毒感染后以潜伏形式长期存在于脊神经或颅神经的神经节细胞中,当机体免疫功能减弱时,可诱发水痘带状疱疹病毒活动生长繁殖,沿周围神经波及皮肤,发生带状疱疹。患者发病前常常发热、乏力、全身不适、食欲不振、局部淋巴结肿痛以及患处皮肤灼热、感觉过敏或神经痛等,随之出现成簇而不融合的粟粒至黄豆大丘疹,丘疹继而变为水疱,疱液澄清,疱壁紧张,围以红晕。皮损沿外周神经分布,排列成带状。
目前治疗带状疱疹的方法主要有:
(1)止痛:阿斯匹林、安乃近、消炎痛、布洛芬、新癀片等。疱疹后神经痛需止痛剂和镇静剂合用,如多虑平;甲氰咪胍、地塞米松、赛庚啶;维生素B12肌注,共用10天。
(2)局部皮肤护理治疗;酞丁胺擦剂或炉甘石洗剂外搽。糜烂者涂2%龙胆紫溶液或涂新霉素糠馏油糊剂。或紫外线照射、音频电疗,激光照射,TDP频谱照射等。
(3)眼部带状疱疹:可用疱疹净或无环鸟苷液滴眼;
(4)抗病毒治疗:阿糖腺苷或无环鸟苷,主要用于免疫缺陷或免疫抑制的病人。口服阿昔洛韦、万乃洛韦等高效抗病毒药;外用阿昔洛韦眼药水、口服抗菌药或外用红霉素软膏涂患处。如果水泡破裂,可用2.5%龙胆紫溶液涂患处。
(5)清热解毒的中药和针刺疗法。带状疱疹属于肝火炽盛者,口服龙胆泻肝丸;属于脾虚湿困者,口服胃苓丸或参苓白术丸;属于气血淤滞者,口服血府逐瘀丸。
治疗带状疱疹的口服西药主要有:抗病毒药、止痛药、免疫调节剂、皮质激素等。抗病毒药有阿昔洛韦、万乃洛韦、阿糖腺苷、无环鸟苷及干扰素等。消炎止痛药如阿斯匹林、去痛片、维生素B1、维生素B12等。局部患处外用药有:2%龙胆紫溶液或复方地榆氧化锌油外涂。若有继发感染,可用新霉素软膏外搽。
上述治疗方法和治疗药物均能缓解疼痛,消除临床疱疹疹状,但是西药治疗存在疗程长、损害肝肾,副作用大,治疗费用昂贵,而且患者容易产生神经痛后遗症和治愈后容易复发等缺点。
目前,采用中药治疗带状疱疹越来越收到人们的重视,但是中药种类和制备药物的方法各不相同。例如公开号为CN101028494的中国专利申请公开了一种治疗带状疱疹的中药汤剂,它是以延胡索、板蓝根、三棱、没药、板蓝根、郁金、橘皮、大黄、乳香、三七、甘草、莪术和白芷等10多味中草药为原料制成。公开号为CN101264184的中国专利申请公开了一种治疗带状疱疹的中药组合物。该中药组合物由元胡、川芎、白花蛇舌草、泽泻、板蓝根、枳壳、川楝子、红花、生栀子、丹皮、赤芍、马齿苋、黄芩、车前子、桃仁、大青叶、胆草、鸡血藤、茯苓皮、路路通和/或药学上可接受的载体制成。
发明内容
本发明的首要目的是针对上述问题提供一种用于治疗带状疱疹的组合物及其制备方法,该组合物针对带状疱疹形成的病因和病机,利用多种中药的活性成分的相互协同作用,通过清热解毒,燥湿止痛、化瘀败毒、去腐生肌,治疗带状疱疹,而且不留疤痕和神经痛等后遗症。
为实现本发明的目的,本发明一方面提供一种用于治疗带状疱疹的组合物,主要包括如下原料制成:黄连、黄芩、黄柏、大黄、龙胆草、紫草、赤芍、当归、青黛、虎仗、连翘、栀子。
其中,治疗带状疱疹的组合物原料的重量份配比为:黄连3-20、黄芩2-15、黄柏3-15、大黄2-20、龙胆草3-15、紫草2-20、赤芍5-20、当归8-18、青黛1-10、虎仗5-30、连翘5-25、栀子2-20。
特别是,所述原料的重量份配比优选为:黄连5-10、黄芩5-10、黄柏5-10、大黄6-10、龙胆草5-10、紫草6-10、赤芍10-15、当归10-15、青黛4-8、虎仗10-20、连翘10-20、栀子5-10。
本发明的治疗带状疱疹的组合物遵循中医“君臣佐使”的组方原则,以黄连、虎仗、黄芩和黄柏为君药;赤芍、龙胆草、青黛、连翘为臣药;大黄、栀子、紫草和当归为佐使药,组合制备而成。诸药相合,清热解毒、燥湿止痛、活血化瘀、去腐生肌,各药材中的活性成分相互协同作用,从而轻松治疗带状疱疹,达到标本兼治的效果。
其中,黄连又称云连、雅连、川连、味连、鸡爪连,为毛茛科植物黄连、三角叶黄连或云连的干燥根茎。性寒味苦,归心、脾、胃、肝、胆、大肠经。具有清热燥湿,泻火解毒。用于治疗热病邪入心经之高热;烦躁;谵妄或热盛迫血妄行之吐衄;湿热痞满,呕吐吞酸,泻痢,黄疸,高热神昏,心火亢盛,心烦不寐,血热吐衄,目赤,牙痛,消渴,痈肿疔疮;外治湿疹,湿疮,耳道流脓。酒黄连善清上焦火热。用于目赤,口疮。黄连中主要含有小檗碱、黄连碱、表小檗碱、小檗红碱、药根碱、木兰花碱、甲基黄连碱、掌叶防己碱、非洲防己碱等生物碱,还含黄柏酮、阿魏酸、黄柏内酯等成分。
现代药理研究表明黄连具有抗菌、抗真菌作用,抗病毒作用,抗炎和抗腹泻作用等。黄连煎剂对流感病毒PR8株、甲型流感病毒56-S8株、亚甲型病毒FMl株、乙型流感病毒Lee株、内型流感病毒1233株均有抑制作用;对乙型肝炎病毒DNA有抑制作用。
黄芩为唇形科植物黄芩的干燥根,以清火、养阴、败毒为主,气微,味苦,性寒,归肺、胆、脾、大肠、小肠经,具有清热燥湿,泻火解毒,止血,安胎的作用,主要用于治疗温热病、上呼吸道感染、肺热咳嗽、湿热黄胆、肺炎、痢疾、咳血、目赤、胎动不安、高血压、痈肿疖疮等症。
黄芩含有的化学成分主要是黄酮类化合物,主要有黄芩甙元、黄芩甙、汉黄芩素、汉黄芩甙、黄芩新素、木蝴蝶素A、黄芩黄酮等,还含有苯乙酮、棕榈酸、油酸、脯氨酸、苯甲酸、黄芩酶、β-谷甾醇、菜油甾醇及豆甾醇等。黄芩具有抗炎、抗变态反应、抗微生物的作用,降压、利尿作用,解热、解痉和镇静作用。黄芩的临床应用抗菌比黄连还好,而且不产生抗药性。
黄柏为芸香科植物黄皮树或黄檗的干燥树皮,又称黄檗、元柏、檗木。黄柏性寒,味苦,归肾、膀胱经,具有清热燥湿,泻火除蒸,解毒疗疮之功效,用于治疗湿热泻痢,黄疸,带下,热淋,脚气,骨蒸劳热,盗汗,遗精,疮疡肿毒,湿疹瘙痒。盐黄柏滋阴降火。用于阴虚火旺,盗汗骨蒸。
黄柏含有如下化学成分:小檗碱、药根碱、木兰花碱、黄柏碱、小檗红碱、N-甲基大麦芽碱、掌叶防己碱、白栝楼碱、胍、蝙蝠葛碱等生物碱;另含黄柏酮、黄柏内酯、白鲜交酯、黄柏酮酸、青萤光酸、7-脱氢豆甾醇、豆甾醇、β-谷甾醇、菜油甾醇、黄柏甙、脱氢黄柏甙、脱氢异黄柏甙、白鲜交酯、24-亚甲基环木菠萝醇、牛奶树醇-B、异黄柏甙金丝桃甙和挥发油。
药理研究表明黄柏具有(1)抗菌作用,其抗菌有效成分为小檗碱。黄柏对金黄色葡萄球菌、肺炎球菌、白喉杆菌、草绿色链球菌、痢疾杆菌等均有效。(2)降压作用,降压作用显著而持久,因此降压可能是中枢性的。(3)镇咳作用,抗炎和抗溃疡的作用。(4)增强免疫功能的作用。黄柏临床应用于治疗流行性脑脊髓膜炎、细菌性痢疾、肺炎、肺结核、肝硬化、慢性肝炎、极性结膜炎、慢性化脓性中耳炎等病疹。
大黄别名将军、生军、川军,为蓼科植物掌叶大黄、唐古特大黄或药用大黄的干燥根及根茎。大黄性寒,味苦,归脾、胃、大肠、肝、心包经。具有泻热通肠,凉血解毒,逐瘀通经的功能,用于治疗实热便秘,积滞腹痛,泻痢不爽,湿热黄疸,血热吐衄,目赤,咽肿,肠痈腹痛,痈肿疔疮,瘀血经闭,跌打损伤。
大黄中的主要药效成分有蒽类衍生物、苷类化合物、鞣质类、有机酸类、挥发油类等。蒽类衍生物:①游离蒽醌衍生物,如芦荟大黄素、土大黄素、大黄酚、大黄素、异大黄素、大黄素甲醚、大黄酸;②结合蒽醌化合物:大黄酸、芦荟大黄素、大黄酚的单和双葡萄糖甙;大黄素、大黄素甲醚的单糖甙;③蒽酚和蒽酮化合物:大黄二蒽酮、掌叶二蒽酮以及与糖结合的甙如番泻甙A、B、C、D、E、F等。苷类化合物:土大黄甙、3,5,4’-三羟基芪烯一4’-O-β-D-(6’-O-没食子酰)葡萄糖甙、3,5,4’-三羟基茋烯-4’-O-β-D-吡喃葡萄糖甙等。鞣质类:没食子酰葡萄糖、d-儿茶素、没食子酸、大黄四聚素等。大黄四聚素经水解,得没食子酸、肉桂酸及大黄明。此外还含挥发油、植物甾醇、树脂和有机酸等。
大黄的药理研究表明大黄具有泻下作用,大黄中的番泻甙在肠道细菌酶的作用下分解产生大黄酸蒽酮,大黄酸蒽酮刺激大肠粘膜,使肠蠕动增加而泻下。另外还可抑制肠细胞膜上Na+、K+-ATP酶,阻碍Na+转运,使肠内渗透压升高,保留大量水分,促进肠蠕动而泻下;止血作用,其有效成分α-儿茶素、没食子酸可以促进血小板的粘附和聚集功能,增加血小板数和纤维蛋白原含量,降低抗凝血酶III活性,使受伤局部的血管收缩,进而止血。抗感染作用,大黄中的抗菌有效成分为大黄酸、大黄素、芦荟大黄素,大黄能抑制细菌核酸和蛋白质合成;抑制细菌生物氧化酶系统;诱生干扰素。
龙胆草为龙胆科植物条叶龙胆、龙胆、三花龙胆、或坚龙胆的干燥根及根茎,又称龙胆、苦胆草、胆草。龙胆草性寒,味苦,归肝、胆经,具有清热燥湿,泻肝定惊的作用。主要用于治疗湿热黄疸,小便淋痛;阴肿阴痒;湿热带下;肝胆实火之头胀头痛;目赤肿痛;耳聋耳肿;胁痛口苦;热病惊风抽搐、惊痫狂躁,乙型脑炎等疹。龙胆草的化学成分主要有:裂环烯醚萜甙类苦味成分:龙胆苦甙、当药苦甙、当药甙、苦龙胆酯甙、痕量苦当药酯甙;苦甙总含量可高达7.33%,而龙胆苦甙含量可达6.34%;还含有生物碱:龙胆碱即秦艽碱甲,乙,丙、龙胆黄碱。
药理研究表明龙胆草具有的药理作用如下:龙胆苦苷能促进胃液和胃酸分泌,增加游离盐酸和增进食欲的作用;龙胆对肝脏急性损伤有保护作用,能减轻肝坏死和肝细胞病变程度;龙胆草具有保肝利胆的作用;龙胆碱对中枢神经系统有兴奋作用,但较大剂量时则出现麻醉作用。
紫草别名硬紫草、软紫草,是紫草科植物新疆紫草、紫草或内蒙紫草的干燥根。紫草性寒,味苦、咸,归心、肝经,具有清热凉血,活血,解毒透疹的功效。主要用于治疗血热毒盛,斑疹紫黑,麻疹不透,疮疡,湿疹,水火烫伤,清热凉血,用于麻疹,热病癍疹,湿疹,尿血,血淋,血痢,疮疡,丹毒,烧伤,热结便秘。
紫草中含有乙酰紫草醌、异丁酰紫草醌、β,β-二甲基丙烯紫草醌、β-羟基异戊酰紫草醌、3,4-二甲基戊烯-3-酰基紫草醌等。紫草有抗菌、抗炎作用,对病毒具有抑制作用,对金黄色葡萄球菌、灵杆菌、化脓菌、大肠杆菌等也有抑制作用。紫草醌及乙酰紫草醌还具有抗炎作用,局部应用可促进创伤愈合;对循环系统具有兴奋作用;抗肿瘤作用,对对绒毛膜上皮癌及恶性葡萄胎有一定的疗效;解热和利尿作用。
赤芍为毛茛科植物芍药、草芍药、川赤芍等的根,别称木芍药、红芍药。赤芍性微寒、味酸、苦,归肝、脾经。具有清热凉血,散瘀止痛的功能,主要用于温毒发斑,吐血衄血,目赤肿痛,肝郁胁痛,经闭痛经,症瘕腹痛,跌扑损伤,痈肿疮疡。
赤芍主要含有芍药甙,氧化芍药甙,苯甲酰芍药甙,白芍甙,芍药甙无酮,没食子酰芍药甙,芍药新甙,芍药内酯等,还含有β-谷甾醇,胡萝卜甙,食子酰基葡萄糖,右旋儿茶精和挥发油,其中挥发油主要含苯甲酸,牡丹酚及其他醇类和酚类成分。芍药甙在根中含量高,全在根皮部分。现代药理研究说明赤芍具有解痉;降压、增加血流;镇痛、镇静、抗惊厥;抗炎、抗溃疡;抗菌、解热等药理作用。
当归为伞形科植物当归的干燥根,性温,味辛、甘,归肝、心、脾经,具有补血活血,调经止痛,润肠通便值之功效,主要用于治疗血虚萎黄,眩晕心悸,月经不调,经闭痛经,症瘕结聚,虚寒腹痛,肠燥便秘,风湿痹痛,跌扑损伤,痈疽疮疡。当归中挥发油主要有藁本内酯、亚丁基苯酞、邻羧基苯正戊酮及δ-2,4-二氢酞酐;还还有倍半萜烯类化合物:正丁烯夫内酯、邻羧基苯正戊酮以及蔗糖、维生素B12、维生素A类物、有机酸及生物素;当归根还含阿魏酸、丁二酸、菸酸、尿嘧啶、腺嘌呤、东莨菪素、伞形酮、香荚兰酸、及胆碱,醚溶性部分含镰叶芹醇、镰叶芹酮、镰叶芹二醇等。
当归具有抗肿瘤、抗辐射、镇痛、平喘作用;对中枢神经系统的抑制作用,当归中的挥发油起到镇静、催眠、镇痛、麻醉等作用;当归的抗菌、消炎作用。临床可用于化脓性上颌窦炎、急性肾炎、骼静脉炎、硬皮病及牛皮癣等病症。当归热水提取物对慢性风湿性病实验动物模型在其佐剂关节炎急性发作时有明显的抑制作用;当归对脑缺氧、缺血后再灌注脑组织脂质过氧化物增高有明显的抑制作用。当归所含的阿魏酸直接减少H2O2含量,并与膜磷脂酰乙醇胺结合,通过直接消除自由基,抑制氧化反应和自由基反应等拮抗自由基对组织的损害。
青黛是爵床科植物马蓝、蓼科植物蓼蓝或十字花科植物菘蓝的叶或茎叶经加工制得的干燥粉末或团块,为深蓝色的粉末;或呈不规则多孔性的团块。微有草腥气,味淡,性寒,味咸,归肝、肺、胃经,具有清热解毒,清肝泻火,凉血,定惊的作用,主要用于温毒发斑,血热吐衄,胸痛咳血,口疮,痄腮,喉痹,小儿惊痫,肝热惊痫,肝火犯肺咳嗽,咽喉肿痛,丹毒,疮肿,蛇虫咬伤。
青黛主要含有靛蓝、靛玉红,因产地、原料及制取方法不同,产品中含靛蓝量有差异。另外还含N-苯基-2-荼胺、β-谷甾醇、虫漆蜡醇、靛甙、松蓝甙B、色氨酮、青黛酮、靛红和正二十九烷等。现代药理研究表明青黛醇浸液在体外对炭疽杆菌、肺炎杆菌、志贺氏痢疾杆菌、霍乱弧菌、金黄色和白色葡萄球菌均有抑制作用。
虎杖为蓼科植物虎杖的干燥根茎和根。性微寒、味微苦,归肝、胆、肺经,具有祛风利湿,散瘀定痛,止咳化痰,用于治疗关节痹痛,湿热黄疸,经闭,症瘕,水火烫伤,跌扑损伤,痈肿疮毒,咳嗽痰多。虎杖中含有游离葸醌及蒽醌甙,主要为大黄素、大黄素甲醚和大黄酚,以及蒽甙A、蒽甙B。根中还含3,4’,5-三羟基芪-3-β-D-葡萄糖甙,还含有鞣质、多糖和异槲皮甙等。
虎杖的药理作用主要表现如下:(1)虎杖煎液对金黄色葡萄球菌、卡他球菌、甲型或乙型链球菌、大肠杆菌、绿脓杆菌有抑制作用,高浓度虎杖煎液对钩端螺旋体也有杀灭作用;(2)虎杖水煎液对流感亚洲甲型京科68-1株病毒、孤儿病毒、单纯疱疹病毒、腺病毒3型,脊髓灰白质炎II型,肠道病毒柯萨奇A、B组,爱可组,乙型脑炎京卫研1号,单纯疱疹一株均有明显的抑制作用。
连翘为木犀科植物连翘的干燥果实,性微寒,味苦,归肺、心、小肠经。连翘具有清热解毒,消肿散结的功能,主要用于治疗痈疽,瘰疠,乳痈,丹毒,风热感冒,温病初起,温热入营,高热烦渴,神昏发斑,热淋尿闭。
连翘含木脂体类化合物:连翘甙及甙元、右旋松脂酚、右旋松脂醇葡萄糖甙等;黄酮类化合物:芸香甙等;苯乙烷类衍生物:连翘脂甙A、C、D、E、连翘种甙、毛柳甙;乙基环己醇类衍生物:连翘环己醇、异连翘环己醇、连翘环己醇氧化物、连翘环己醇酮;三萜类化合物:白桦脂酸、齐墩果酸、熊果酸等。
连翘浓缩煎剂在体外有抗菌作用,可抑制伤寒杆菌、副伤寒杆菌、大肠杆菌、痢疾杆菌、白喉杆菌及霍乱弧菌、葡萄球菌、链球菌等,连翘酚为抗菌的有效成分;连翘的醇提取物在体外有抗钩端螺旋体作用;连翘水浸剂在试管内对星形奴卡氏菌有些抑制作用;连翘能抑制催吐作用,连翘的镇吐作用原理可能是抑制延脑的催吐化学感受区。连翘的果皮中含齐墩果酸(又名洋橄榄叶酸),故有强心、利尿作用。
栀子的别名为黄栀子、山栀子、红枝子,为茜草科植物栀子的成熟果实和根,性寒、味苦,归心、肺、三焦经。栀子的果实具有泻火除烦,清热利尿,凉血解毒的功效,主要用于热病心烦,黄疸尿赤,血淋涩痛,血热吐衄,目赤肿痛,火毒疮疡。栀子的根具有泻火解毒,清热利湿,凉血散瘀之功能,用于治疗传染性肝炎,跌打损伤,风火牙痛。
栀子中含有环烯醚萜类成分:栀子甙、都桷子甙、山栀甙、栀子酮甙、鸡屎藤次甙甲酯、都桷子甙酸等;酸类成分:绿原酸、3,4-二-O-咖啡酰其奎宁酸、藏红花酸、藏红花素、熊果酸、藏红花素葡萄糖甙等。黄酮类成分:芸香甙以及D-甘露醇、β-谷甾醇、胆碱、二十九烷、叶黄素等。栀子水提取液及醇提取液能促进胆汁分泌,利胆的作用,静脉注射藏红花素和藏红花酸钠后,胆汁分泌量增加。栀子还具有镇静、降压的作用,降压作用持久而且迅速。栀子水漫液对许兰氏黄癣菌,腹股沟表皮癣菌、红色表皮癣菌等多种真菌有抑制作用,能杀死钩端螺旋体以及能使血吸虫停止活动。
本发明用于治疗带状疱疹的组合物也可以与药学上可接受的载体,例如:填充剂如淀粉、微晶纤维素等;黏合剂如纤维素衍生物、淀粉等;崩解剂如羧甲基纤维素钠、低取代羟丙基纤维素等,通过散剂、片剂、丸剂、颗粒剂等口服给药的方式服用。
本发明另一方面提供一种治疗带状疱疹组合物的制备方法,包括如下步骤:
1)按照以下重量份配比准备原料:
黄连3-20、黄芩2-15、黄柏3-15、大黄2-20、龙胆草3-15、紫草2-20、赤芍5-20、当归8-18、青黛1-10、虎仗5-30、连翘5-25、栀子2-20;
2)将原料混合均匀后,对混合物进行加热提取,收集提取液;
3)将收集的提取液浓缩,制成本发明药物的活性成分。
其中,所述的原料的用量优选为:黄连5-10、黄芩5-10、黄柏5-10、大黄6-10、龙胆草5-10、紫草6-10、赤芍10-15、当归10-15、青黛4-8、虎仗10-20、连翘10-20、栀子5-10;
其中,步骤2)中,将所述各原料粉碎后进行混合,所述加热提取包括如下步骤:
A)将混合物加入水浸泡,加入的水的重量与混合物的重量之比为3-6∶1,浸泡20-90分钟后进行第一次加热提取,加热温度为100℃,加热提取时间为1-5小时;
B)将第一次提取液进行过滤,收集滤液;
C)向滤渣中加入水,进行第二次加热提取,其中,加入的水的重量与混合物的重量之比为1-5∶1,加热温度为100℃,加热提取时间为1-3小时;
D)过滤,将两次过滤的滤液合并。
特别是,将所述原料粉碎成粒度为10-50目的粗粉后进行所述的混合;步骤A)中所述的浸泡时间优选为30-60分钟,加入的水的重量与混合物的重量之比优选为4-6∶1,第一次加热提取时间优选为1-3小时;步骤C)中加入的水的重量与混合物的重量之比为1-3∶1。
其中,步骤3)中进行所述提取液浓缩时,控制温度为80-100℃,优选为100℃;所述提取液浓缩至比重为1.05-1.50浓缩液,比重优选为1.10-1.35。
本发明药物的活性成分可以加入制备不同剂型时所需的各种常规辅料,如崩解剂、润滑剂、黏合剂等以常规的中药制剂方法制备成任何一种常用的口服剂型,如丸剂、散剂、片剂、颗粒剂、胶囊剂、口服液等。
本发明制备的治疗带状疱疹组合物使用时,每天口服1-2,每次5-7克(生药),孕妇禁止服用,用药期间禁止食用辛辣、生冷、海鲜、油腻的食物以及禁烟,连续使用5-10天后,疼痛感消除,带状水泡消失,皮肤红肿恢复,愈后无红斑或色素沉着,不留疤痕。
本发明的治疗带状疱疹组合物是基于中医学对带状疱疹的发病机理的充分认识和提高机体免疫力的治疗原则,结合现代药学和药理学研究的成果,通过对黄连、黄芩、黄柏、大黄、龙胆草、紫草、赤芍、当归、青黛、虎杖、连翘、栀子进行科学组方制备而成,以纯天然的野生中药材为原料,无毒副作用,通过清热解毒、燥湿止痛、活血化瘀、去腐生肌,达到标本兼治的功效,具有作用直接,起效迅速,疗程短,疗效显著,不复发,无毒副作用、服用方便,价格低廉等优点。
本发明制备的治疗带状疱疹的组合物具有如下优点:
1、本发明所述的治疗带状疱疹组合物针对带状疱疹的发病原因对症治疗。本发明的治疗带状疱疹组合物由多种中药成分复合而成,其中的药物的活性成分,相互协同作用,直接针病因,针对带状疱疹的各种形成原因进行综合调理,治疗效果快,作用迅速,疗程短,一般1-2天内就可以止痛,皮肤损伤开始好转,5-6天内所有疹状基本消失。
2、本发明制备的治疗带状疱疹组合物,采用天然药材合理复配而成,从调节人体脏器着手,疏通经络,通过根除带状疱疹发病的内因治疗,因此,本发明的产品具有标本兼治、预防和治疗带状疱疹的多重功效,而且治愈率高,达到97%以上,愈后不复发,无后遗症。
3、本发明制备的治疗带状疱疹组合物无毒副作用,制备工艺简单,产品质量稳定效果明显,并且使用方便。
具体实施方式
以下通过实验例来进一步阐述本发明所述治疗带状疱疹组合物的临床治疗效果。
试验例1 本发明治疗带状疱疹组合物治疗带状疱疹效果的临床观察
(一)一般资料:
本发明治疗带状疱疹组合物(散剂)共经过120例观察了解治疗效果,其中男性患者60例,女性患者60例,年龄18-65岁,将病例随机分为治疗组和对照组,其中治疗组70例,对照组50例,均确诊为带状疱疹且发病在7天以内,无其他并发症和继发症,两组病例在年龄、性别、病程上均无显著差异。
(二)带状疱疹的诊断标准:(戴慎等主编《中医病证诊疗标准与方剂选用》)
1、皮损多为绿豆大小的水疤,簇集成群,疤壁紧张,基底色红,常单侧分布,排列成带状。严重者皮损可表现为出血性,或可见坏疽性损害。皮损发于头面部者,病情往往较重。
2、皮疹出现前,常先有皮肤刺痛或烧灼感,可伴有周身轻度不适,发热。
3、自觉疼痛明显,可有难以忍受的剧痛,或皮疹消退后遗疼痛。
(三)治疗方法
治疗组:每天口服本发明治疗带状疱疹组合物(散剂)2次,每次5-7克(生药),连续用药5-10天,用药期间禁止食用辛辣、生冷、海鲜、油腻的食物以及禁烟;
对照组:每日口服阿昔洛韦片,3次/日,0.2g/次。
(四)带状疱疹治疗效果评定标准:(戴慎等主编《中医病证诊疗标准与方剂选用》)
1、治愈:皮疹消退,临床体征消失,无疼痛后遗症。
2、好转:皮疹消退约30%,疼痛明显减轻。
3、未愈:皮疹消退不足30%,仍有疼痛。
(五)临床试验结果
实验结果如表1、2所示。
表1带状疱疹治疗结果表
治愈(例) | 好转(例) | 未愈(例) | 治愈率(%) | |
治疗组(70例) | 68 | 2 | 0 | 97.1% |
对照组(50例) | 46 | 3 | 1 | 92% |
表2带状疱疹治愈结果表
1-2天治愈(例) | 3-5天治愈(例) | 6-10天治愈(例) | 10天以上治愈(例) | |
治疗组 | 7 | 12 | 45 | 4 |
对照组 | 0 | 0 | 9 | 37 |
结果表明:
1、本发明治疗带状疱疹组合物治疗效果显著,带状疱疹的临床疹状明显消退;治愈率达到97.1%,好转率达到2.9%,总有效率达到100%。
2、本发明治疗带状疱疹组合物作用迅速,见效快,疗程短,治疗6-10天后患者治愈率达到91.4%,其中:1-2天的治愈率达到10%;3-5天的治愈率达到17.1%;6-10天的治愈率达到64.3%;而对照组的治愈时间长,需要至少治疗5天以上。
3、本发明的药物组合物无任何毒副作用、过敏反应及其他不良反应,说明本发明的用于治疗带状疱疹组合物对人体无不良影响。
4、对受试者使用本发明产品后,跟踪观察6-12个月未出现带状疱疹复发现象。
试验例2 本发明治疗带状疱疹组合物临床药理、毒理试验
(一)急性毒性试验
将本发明的治疗带状疱疹组合物散剂对昆明小鼠灌服1000g(生药)/kg。未出现任何毒性反应,一周内无动物死亡。
(二)长期毒性试验
将本发明的治疗带状疱疹组合物片剂对大鼠进行长期毒性试验,连续大剂量(成人剂量的100倍)灌胃给药,给药时间长(90天),以动物给药前后的一般表现、体重、摄食量、血液学及血清生化指标、尿常规、骨髓分类、脏器重量、脏器系数为检测指标,并辅以动物各组织脏器的病理学检查,综合评价药物的毒性情况。结果显示大鼠的各项指标均正常。病理组织学检查结果显示,大鼠各组织脏器未见异常。
综上所述:本发明的治疗带状疱疹组合物毒性低,安全范围广。
实施例1 本发明药物的胶囊剂制备
1)按照以下配比称取原料(单位:g)
黄连5、黄芩15、黄柏10、大黄10、龙胆草5、紫草20、赤芍10、当归8、青黛4、虎仗10、连翘25、栀子5
其中,将黄连、黄芩、黄柏、大黄、龙胆草、紫草、赤芍、当归、青黛、虎仗、连翘、栀子分别粉碎成粗粉,粗粉的粒度为24-50目,混合均匀,制成粗粉混合物后备用;
2)将混合均匀的粗粉混合物置于中药多功能提取釜中,加入自来水浸泡30分钟,加入的自来水的重量与粗粉混合物的重量之比为6∶1;
3)开启多功能提取釜电源进行加热,加热至100℃,保持在此温度下恒温提起2小时,然后过滤,得到第一次提取液备用;
4)向滤渣中加入自来水,加入的自来水的重量与粗粉混合物的重量之比为3∶1,加热提取,加热温度为100℃,提取时间为1小时,过滤得到第二次提取液;
5)将2次提取液合并后进行浓缩,浓缩成比重为1.30的浸膏,然后于45-50℃下进行干燥,得到干浸膏;
6)将干浸膏粉碎成100-150目的细粉后装入明胶硬胶囊,即得。
实施例2 本发明药物的片剂制备
1)按照以下配比称取原料(单位:g)
黄连10、黄芩2、黄柏5、大黄20、龙胆草10、紫草2、赤芍15、当归10、青黛1、虎仗30、连翘5、栀子2
其中,将黄连、黄芩、黄柏、大黄、龙胆草、紫草、赤芍、当归、青黛、虎仗、连翘、栀子分别粉碎成粗粉,粗粉的粒度为24-50目,混合均匀,制成粗粉混合物后备用;
2)将混合均匀的粗粉混合物置于中药多功能提取釜中,加入自来水浸泡60分钟,加入的自来水的重量与粗粉混合物的重量之比为4∶1;
3)开启多功能提取釜电源进行加热,加热至100℃,保持在此温度下恒温提起1.5小时,然后过滤,得到第一次提取液备用;
4)向滤渣中加入自来水,加入的自来水的重量与粗粉混合物的重量之比为3∶1,加热提取,加热温度为100℃,提取时间为1.5小时,过滤得到第二次提取液;
5)将2次提取液合并后进行浓缩,浓缩成比重为1.35的浸膏,然后于45-50℃下进行干燥,得到干浸膏;
6)将干浸膏粉碎成细粉,加入辅料制成颗粒,并干燥,压制成片。
实施例3 本发明药物的丸剂制备
1)按照以下配比称取原料(单位:g)
黄连3、黄芩10、黄柏15、大黄6、龙胆草3、紫草10、赤芍20、当归15、青黛8、虎仗20、连翘10、栀子10
其中,将黄连、黄芩、黄柏、大黄、龙胆草、紫草、赤芍、当归、青黛、虎仗、连翘、栀子分别粉碎成粗粉,粗粉的粒度为24-50目,混合均匀,制成粗粉混合物后备用;
2)将混合均匀的粗粉混合物置于中药多功能提取釜中,加入自来水浸泡20分钟,加入的自来水的重量与粗粉混合物的重量之比为5∶1;
3)开启多功能提取釜电源进行加热,加热至100℃,保持在此温度下恒温提起3小时,然后过滤,得到第一次提取液备用;
4)向滤渣中加入自来水,加入的自来水的重量与粗粉混合物的重量之比为1∶1,加热提取,加热温度为100℃,提取时间为1小时,过滤得到第二次提取液;
5)将2次提取液合并后进行浓缩,浓缩成比重为1.25的浸膏,然后于45-50℃下进行干燥,得到干浸膏;
6)将干浸膏粉碎成细粉后与辅料炼蜜混合,搅拌均匀后置于制丸机中进行制丸,制好的药丸于干燥箱中干燥至成品。。
实施例4 本发明药物的颗粒剂制备
1)按照以下配比称取原料(单位:g)
黄连20、黄芩5、黄柏3、大黄2、龙胆草15、紫草6、赤芍5、当归18、青黛10、虎仗5、连翘20、栀子20
其中,将黄连、黄芩、黄柏、大黄、龙胆草、紫草、赤芍、当归、青黛、虎仗、连翘、栀子分别粉碎成粗粉,粗粉的粒度为24-50目,混合均匀,制成粗粉混合物后备用;
2)将混合均匀的粗粉混合物置于中药多功能提取釜中,加入自来水浸泡90分钟,加入的自来水的重量与粗粉混合物的重量之比为3∶1;
3)开启多功能提取釜电源进行加热,加热至100℃,保持在此温度下恒温提起1小时,然后过滤,得到第一次提取液备用;
4)向滤渣中加入自来水,加入的自来水的重量与粗粉混合物的重量之比为3∶1,加热提取,加热温度为100℃,提取时间为2小时,过滤得到第二次提取液;
5)将2次提取液合并后进行浓缩,浓缩成比重为1.30的浸膏,然后于45-50℃下进行干燥,得到干浸膏;
6)将干浸膏粉碎成细粉,在加入乙醇作黏合剂,加入辅料淀粉制成颗粒。
实施例5 本发明药物的口服液的制备
1)按照以下配比称取原料(单位:g)
黄连7.5、黄芩7.5、黄柏7.5、大黄8、龙胆草7.5、紫草8、赤芍12.5、当归12.5、青黛6、虎仗15、连翘15、栀子12.5
其中,将黄连、黄芩、黄柏、大黄、龙胆草、紫草、赤芍、当归、青黛、虎仗、连翘、栀子分别粉碎成粗粉,粗粉的粒度为24-50目,混合均匀,制成粗粉混合物后备用;
2)将混合均匀的粗粉混合物置于中药多功能提取釜中,加入自来水浸泡45分钟,加入的自来水的重量与粗粉混合物的重量之比为6∶1;
3)开启多功能提取釜电源进行加热,加热至100℃,保持在此温度下恒温提起2小时,然后过滤,得到第一次提取液备用;
4)向滤渣中加入自来水,加入的自来水的重量与粗粉混合物的重量之比为2∶1,加热提取,加热温度为100℃,提取时间为3小时,过滤得到第二次提取液;
5)将2次提取液合并后进行浓缩,浓缩至比重为1.10的浓缩液;
6)将浓缩液分装于塑料复合膜包装中,制成口服液。
Claims (10)
1、一种治疗带状疱疹的药物组合物,其特征是包括以下原料:黄连、黄芩、黄柏、大黄、龙胆草、紫草、赤芍、当归、青黛、虎杖、连翘、栀子。
2、如权利要求1所述的组合物,其特征是所述原料的重量份配比为:
黄连3-20、黄芩2-15、黄柏3-15、大黄2-20、龙胆草3-15、紫草2-20、赤芍5-20、当归8-18、青黛1-10、虎仗5-30、连翘5-25、栀子2-20。
3、如权利要求2所述的组合物,其特征是所述原料的重量份配比选择为:
黄连5-10、黄芩5-10、黄柏5-10、大黄6-10、龙胆草5-10、紫草6-10、赤芍10-15、当归10-15、青黛4-8、虎仗10-20、连翘10-20、栀子5-10。
4、一种治疗带状疱疹的药物组合物的制备方法,包括下列步骤:
1)按照以下重量份配比备料:
黄连3-20、黄芩2-15、黄柏3-15、大黄2-20、龙胆草3-15、紫草2-20、赤芍5-20、当归8-18、青黛1-10、虎仗5-30、连翘5-25、栀子2-20;
2)将原料混合均匀后,对混合物进行加热提取,收集提取液;
3)将收集的提取液浓缩,即得。
5、如权利要求4所述的制备方法,其特征是所述原料的重量份配比为:
黄连5-10、黄芩5-10、黄柏5-10、大黄6-10、龙胆草5-10、紫草6-10、赤芍10-15、当归10-15、青黛4-8、虎仗10-20、连翘10-20、栀子5-10。
6、如权利要求4或5所述的制备方法,其特征是在所述步骤2)中,将所述各原料粉碎后进行所述混合,所述加热提取按照如下步骤进行:
A)将混合物加入水浸泡,加入的水的重量与混合物的重量之比为3-6∶1,浸泡20-90分钟后进行第一次加热提取,加热温度为100℃,加热提取时间为1-5小时;
B)将第一次提取液进行过滤,收集滤液;
C)向滤渣中加入水,进行第二次加热提取,其中,加入的水的重量与混合物的重量之比为1-5∶1,加热温度为100℃,加热提取时间为1-3小时;
D)过滤,将两次过滤的滤液合并。
7、如权利要求6所述的制备方法,其特征是将所述原料粉碎成粒度为10-50目的粗粉后进行所述的混合。
8、如权利要求6所述的制备方法,其特征是步骤A)中所述的浸泡时间优选为30-60分钟,加入的水的重量与混合物的重量之比优选为4-6∶1。
9、如权利要求4或5所述的制备方法,其特征是所述步骤3)中进行所述提取液浓缩时,控制温度为80-100℃,所述提取液浓缩至比重为1.05-1.50浓缩液。
10、如权利要求9所述的制备方法,其特征是浓缩液的比重为1.10-1.35。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101581504A CN101596252B (zh) | 2009-07-14 | 2009-07-14 | 一种治疗带状疱疹的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101581504A CN101596252B (zh) | 2009-07-14 | 2009-07-14 | 一种治疗带状疱疹的组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101596252A true CN101596252A (zh) | 2009-12-09 |
CN101596252B CN101596252B (zh) | 2011-08-10 |
Family
ID=41417970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101581504A Expired - Fee Related CN101596252B (zh) | 2009-07-14 | 2009-07-14 | 一种治疗带状疱疹的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101596252B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102579637A (zh) * | 2012-03-14 | 2012-07-18 | 广西强寿药业集团有限公司 | 一种治疗病毒性疱疹的中成药-疱疹病毒片及其制备方法 |
CN103585416A (zh) * | 2013-11-20 | 2014-02-19 | 钱家美 | 一种治疗带状疱疹的药物组合物 |
CN104758602A (zh) * | 2015-04-02 | 2015-07-08 | 王永帮 | 一种治疗带状疱疹的油膏 |
CN105998231A (zh) * | 2016-07-27 | 2016-10-12 | 肖琼芬 | 一种治疗静脉炎的外用药物及其制备方法 |
CN109045232A (zh) * | 2018-09-21 | 2018-12-21 | 贵州恒华搬家服务有限公司 | 一种治疗疱疹的药酒 |
JP7630764B2 (ja) | 2019-06-26 | 2025-02-18 | 大正製薬株式会社 | 毛髪抗老化剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552492B (zh) * | 2012-01-12 | 2014-04-30 | 山东省千佛山医院 | 一种治疗带状疱疹的中药组合物及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101474281B (zh) * | 2009-01-20 | 2011-04-06 | 袁崇芬 | 带状疱疹消痛膏及其制备方法 |
-
2009
- 2009-07-14 CN CN2009101581504A patent/CN101596252B/zh not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102579637A (zh) * | 2012-03-14 | 2012-07-18 | 广西强寿药业集团有限公司 | 一种治疗病毒性疱疹的中成药-疱疹病毒片及其制备方法 |
CN103585416A (zh) * | 2013-11-20 | 2014-02-19 | 钱家美 | 一种治疗带状疱疹的药物组合物 |
CN104758602A (zh) * | 2015-04-02 | 2015-07-08 | 王永帮 | 一种治疗带状疱疹的油膏 |
CN105998231A (zh) * | 2016-07-27 | 2016-10-12 | 肖琼芬 | 一种治疗静脉炎的外用药物及其制备方法 |
CN109045232A (zh) * | 2018-09-21 | 2018-12-21 | 贵州恒华搬家服务有限公司 | 一种治疗疱疹的药酒 |
JP7630764B2 (ja) | 2019-06-26 | 2025-02-18 | 大正製薬株式会社 | 毛髪抗老化剤 |
Also Published As
Publication number | Publication date |
---|---|
CN101596252B (zh) | 2011-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101596252B (zh) | 一种治疗带状疱疹的组合物及其制备方法 | |
CN103961521A (zh) | 一种用于治疗再生障碍性血液病的中药组合物及制备方法 | |
CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN101502588B (zh) | 一种美容祛痘组合物及其制备方法 | |
CN103893722A (zh) | 一种治疗日光性皮炎的中药组合物及其制备方法 | |
CN104740583A (zh) | 一种用于缓解克罗恩病的中药制剂及其制备方法 | |
CN112237621A (zh) | 一种用于乳腺增生的中药乳膏及其制备方法 | |
CN103656048B (zh) | 用于治疗奶牛乳房炎的药物及其制备方法 | |
CN115282229B (zh) | 一种治疗气虚血淤型冠心病的中药组合物及其制备方法 | |
CN111407808B (zh) | 一种中药组合物及其制备方法与制药应用 | |
CN104623376A (zh) | 用于治疗三叉神经痛的药物 | |
CN104069443A (zh) | 一种治疗急性化脓性骨髓炎的中药及制备方法 | |
CN113499425A (zh) | 一种治疗病毒性感冒的组合物及其制备方法 | |
CN105343346A (zh) | 一种治疗外阴瘙痒的中药片剂及其制备方法 | |
CN104998158A (zh) | 一种治疗肝硬化的药物组合物及其应用 | |
CN105055691A (zh) | 一种高效克服高龄男性勃起功能障碍的中药组合物 | |
CN111658748A (zh) | 用于治疗痛经的组合物、口服制剂及应用 | |
CN103110764A (zh) | 一种治疗急性热毒炽盛型带状疱疹的药物 | |
CN107519261A (zh) | 一种治疗白血病的中药组合物及其制备方法 | |
CN104606638A (zh) | 一种治疗湿热型急性湿疹的药物及其制备方法 | |
CN105233035A (zh) | 治疗耳聋的中药制剂及制法 | |
CN104524460A (zh) | 一种防治急性肾炎的药物组合物及其应用 | |
CN104491557A (zh) | 一种治疗邪阻胃肠型有机磷农药中毒的药物及其制备方法 | |
CN104906352A (zh) | 一种治疗虚火上炎型小儿口疮的中药药液及其制备方法 | |
CN116747279A (zh) | 一种缓解肾虚引发病症的制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110810 Termination date: 20170714 |